This page enables investors and potential investors alike to access core management and financial information in compliance with Rule 26 of the AIM Rules for Companies.

This information was last updated on 13 December 2023.

For information on the following topics, please click on the links below.

Click here to find out more about Allergy Therapeutics.

Allergy Therapeutics plc is incorporated and headquartered in the UK (Company registration number: 5141592). The group’s main manufacturing operations are located in the UK at Dominion Way, Worthing, West Sussex, BN14 8SA.

We mainly sell our products in European countries, contact details for each of our offices can be found here.

Please click here for our Articles of Association.

The Company is not listed on any other exchanges or trading platforms.

Please click here for details of the number of securities in issue, the number of securities held as treasury shares and, insofar as the Company is aware, the percentage of securities that is not in public hands together with the identity and percentage holdings of significant shareholders.

There are no restrictions on the transfer of securities.

Please click here for access to the Company’s annual and interim reports.

Please click here to access the notifications made by the Company in the past 12 months.

Please click here to access the Company’s Admission Document.

Please click here to access the Circular sent to shareholders in April 2023 in relation to the proposed allotment of new shares, disapplication of pre-emption rights and notice of General Meeting.

Please click here to access the Circular sent to shareholders in September 2022 in relation to the proposed subscription of shares and debt financing.

Please click here to access the Circular sent to shareholders on 10 March 2015 in relation to a proposed placing and Notice of General Meeting.

Please click here to access the Circular sent to shareholders on 30 March 2012 relating to a Loan Note instrument

Please click here to access the Circular sent to shareholders in March 2012 in relation to the waiver of Rule 9 of Takeover Code, proposed placing and subscription offer.

Please click here to access the Circular sent to shareholders in June 2009 in relation to the proposed placing, subscription and offer of shares.

Please click here to access the Circular sent to shareholders in September 2023 in relation to the Open Offer.

The Board of Directors have chosen to apply the Quoted Companies Alliance Governance Code (“QCA Code”), on the basis that it is the most suitable governance code for the Group, having regard to its strategy, size, stage of development and resources.

Click here to read the QCA Code Compliance Statement.

Alternatively, you may view our latest Corporate Governance Report describing how the Board has applied the 10 principles set out in the QCA Code in our 2022 Annual Report & Accounts.

Please click here for the names and brief biographical details of the details of the directors together with a description of their responsibilities.

Please click here for information on Directors’ responsibilities and the Board Committee’s

Alternatively, you may view our latest Corporate Governance Report 2022 Annual Report & Account here

The Company is subject to the UK City Code on Takeovers and Mergers.

Please click here for information of the Company’s Nominated Advisor and other key advisors, including contact details.